Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Anti-Inflammatory Agents
COVID-19
/ epidemiology
Comorbidity
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Glucagon-Like Peptide-1 Receptor
/ agonists
Humans
Hypoglycemic Agents
/ therapeutic use
Inflammation
/ prevention & control
Metformin
/ therapeutic use
Pioglitazone
/ therapeutic use
Risk Factors
SARS-CoV-2
Sitagliptin Phosphate
/ therapeutic use
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
C-reactive protein
Dipeptidyl peptidase 4 inhibitors
Ferritin
Glucagon-like peptide-1 receptor agonists
Interleukin 6
Metformin
Pioglitazone
Sodium-glucose co-transporter-2 inhibitors
Journal
Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
06
2020
revised:
21
08
2020
accepted:
21
08
2020
pubmed:
10
9
2020
medline:
15
12
2020
entrez:
9
9
2020
Statut:
ppublish
Résumé
Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.
Identifiants
pubmed: 32900588
pii: S1056-8727(20)30498-0
doi: 10.1016/j.jdiacomp.2020.107723
pmc: PMC7448766
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Metformin
9100L32L2N
Sitagliptin Phosphate
TS63EW8X6F
Pioglitazone
X4OV71U42S
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107723Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest NK has given talks, attended conferences and participated in trials sponsored by Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Mylan, NovoNordisk, Sanofi and Servier. EF has received research support by Boehringher Ingelheim/Lilly&Co., AstraZeneca and Janssen and speaker's honoraria by Boehringer Ingelheim/Lilly&Co., Sanofi and AstraZeneca.
Références
Br J Clin Pharmacol. 2019 Nov;85(11):2512-2523
pubmed: 31338868
Hepatol Res. 2015 Mar;45(3):269-78
pubmed: 24796231
Mediators Inflamm. 2017;2017:5032708
pubmed: 28539704
Int J Clin Pract. 2019 May;73(5):e13335
pubmed: 30810254
Curr Diab Rep. 2019 Nov 27;19(12):151
pubmed: 31776781
Psychoneuroendocrinology. 2016 Nov;73:186-195
pubmed: 27509090
Diabetes. 2006 Apr;55(4):1133-40
pubmed: 16567539
Mediterr J Hematol Infect Dis. 2017 Jan 01;9(1):e2017004
pubmed: 28101310
Diabetes Obes Metab. 2017 Aug;19(8):1147-1154
pubmed: 28244635
Diabetes Res Clin Pract. 2011 Jul;93(1):56-62
pubmed: 21146883
Diabetes Technol Ther. 2012 Jun;14(6):475-84
pubmed: 22512264
Diabetes Obes Metab. 2018 Aug;20(8):1988-1993
pubmed: 29573529
Diabetes Care. 2016 Jan;39(1):139-48
pubmed: 26628419
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1256-1264
pubmed: 30942623
J Atheroscler Thromb. 2020 Jul 1;27(7):644-656
pubmed: 31631099
Nutrients. 2018 Dec 02;10(12):
pubmed: 30513818
Metabolism. 2019 Sep;98:iii-ix
pubmed: 31301336
Diabetes Metab Syndr Obes. 2018 Nov 27;11:835-843
pubmed: 30568471
Diabetes. 2005 May;54(5):1566-72
pubmed: 15855347
Lipids Health Dis. 2017 Dec 2;16(1):227
pubmed: 29197387
Endocr J. 2017 Mar 31;64(3):269-281
pubmed: 27916783
Biochem Pharmacol. 2019 Dec;170:113677
pubmed: 31647926
Acta Diabetol. 2014 Dec;51(6):991-8
pubmed: 25338070
Diabetes Care. 2020 Sep;43(9):2183-2189
pubmed: 32527800
Diabetes Res Clin Pract. 2020 Jun;164:108214
pubmed: 32416121
Cardiovasc Diabetol. 2016 Mar 31;15:54
pubmed: 27036865
J Clin Pharmacol. 2019 Oct;59(10):1391-1399
pubmed: 31131461
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203
pubmed: 31246368
Obes Res Clin Pract. 2017 Sep - Oct;11(5):607-615
pubmed: 28161303
Pharmacology. 2009;84(4):203-10
pubmed: 19738399
Metabolism. 2018 Aug;85:32-37
pubmed: 29452178
Metabolism. 2010 Jun;59(6):887-95
pubmed: 20015525
Diabetologia. 2019 Jul;62(7):1154-1166
pubmed: 31001673
Eur J Clin Invest. 2017 Aug;47(8):600-611
pubmed: 28722106
Metab Brain Dis. 2017 Oct;32(5):1735-1745
pubmed: 28681199
Endocr Pract. 2007 Sep;13(5):444-50
pubmed: 17872344
Pharmacol Rep. 2015 Feb;67(1):24-31
pubmed: 25560571
Mediators Inflamm. 2016;2016:6305735
pubmed: 28104929
Endocr Pract. 2013 Nov-Dec;19(6):980-8
pubmed: 23807528
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2312-8
pubmed: 18818415
Diabetologia. 2017 Sep;60(9):1577-1585
pubmed: 28776086
Curr Diab Rep. 2013 Jun;13(3):435-44
pubmed: 23494755
J Inflamm (Lond). 2016 Nov 24;13:34
pubmed: 27904436
Drug Discov Today. 2019 Jan;24(1):256-262
pubmed: 30086405
Horm Metab Res. 2010 Aug;42(9):663-9
pubmed: 20560108
Atherosclerosis. 2012 Apr;221(2):375-82
pubmed: 22284365
Exp Ther Med. 2019 Jul;18(1):342-351
pubmed: 31258671
Endocr J. 2017 Apr 29;64(4):417-424
pubmed: 28260702
Atherosclerosis. 2019 Sep;288:60-66
pubmed: 31326727
Iran J Basic Med Sci. 2019 Apr;22(4):384-390
pubmed: 31168342
Endocr Rev. 2019 Aug 1;40(4):1080-1091
pubmed: 31127805
Obes Sci Pract. 2018 Aug 22;4(5):477-482
pubmed: 30338118
J Cell Physiol. 2018 Jan;234(1):223-230
pubmed: 30076706
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 32044999
Hormones (Athens). 2015 Jan-Mar;14(1):118-25
pubmed: 25402372
Hypertension. 2014 Oct;64(4):731-7
pubmed: 24980665
Circ J. 2013;77(5):1337-44
pubmed: 23386232
Diabetes Care. 2019 Dec;42(12):2272-2281
pubmed: 31530666
Lipids Health Dis. 2019 Jun 18;18(1):144
pubmed: 31208420
Circulation. 2014 Oct 28;130(18):1579-88
pubmed: 25189213
Cardiovasc Diabetol. 2014 Jul 30;13:110
pubmed: 25074318
Metabolism. 2017 Jun;71:17-32
pubmed: 28521870
Circulation. 2020 Feb 25;141(8):704-707
pubmed: 31707794
Minerva Endocrinol. 2019 Sep;44(3):252-258
pubmed: 29687969
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Diabetol Metab Syndr. 2018 Dec 17;10:91
pubmed: 30564288
Br J Nutr. 2015 Oct 14;114(7):999-1012
pubmed: 26228057
Cardiovasc Diabetol. 2015 May 22;14:61
pubmed: 25994228
Endocrinol Metab (Seoul). 2017 Jun;32(2):241-247
pubmed: 28685513
Diabet Med. 2019 Nov;36(11):1399-1407
pubmed: 30580454
Clin Endocrinol (Oxf). 2007 Feb;66(2):282-9
pubmed: 17224000
J Clin Endocrinol Metab. 2012 Sep;97(9):3333-41
pubmed: 22745245
Endocrine. 2016 Jun;52(3):516-26
pubmed: 26573925
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Ulus Travma Acil Cerrahi Derg. 2019 May;25(3):213-221
pubmed: 31135951
Cardiovasc Diabetol. 2019 Mar 29;18(1):44
pubmed: 30922297
Metabolism. 2013 Mar;62(3):347-51
pubmed: 23062489
Arch Endocrinol Metab. 2020 Aug;64(4):418-426
pubmed: 32267348
Int Immunopharmacol. 2019 Oct;75:105732
pubmed: 31336333
J Diabetes Complications. 2017 Mar;31(3):521-522
pubmed: 28089090
Diabetes Metab J. 2014 Jun;38(3):211-9
pubmed: 25003075
J Endocr Soc. 2019 Nov 19;4(1):bvz017
pubmed: 31993550
Diabetes Res Clin Pract. 2019 Mar;149:140-146
pubmed: 30716347
J Diabetes Res. 2019 Apr 30;2019:6423987
pubmed: 31183384
Diabetol Metab Syndr. 2014 Sep 24;6(1):103
pubmed: 25285158
Diabetes Res Clin Pract. 2020 Apr;162:108142
pubmed: 32278764
J Endocrinol Invest. 2005 Feb;28(2):145-50
pubmed: 15887860
Metabolism. 2018 Jan;78:13-42
pubmed: 28920861
Diabet Med. 2008 Sep;25(9):1129-31
pubmed: 19183322
Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205
pubmed: 25772174
Cell Metab. 2017 Jul 5;26(1):27-38
pubmed: 28506519
Vasc Health Risk Manag. 2008;4(2):297-304
pubmed: 18561505
Diabetol Metab Syndr. 2018 Dec 18;10:93
pubmed: 30574207
Cell Physiol Biochem. 2019;52(1):27-39
pubmed: 30790503
J Inflamm Res. 2019 Oct 21;12:285-291
pubmed: 31695471
Diabetes Care. 2012 Oct;35(10):2076-82
pubmed: 22688551
Diabetol Metab Syndr. 2015 May 17;7:44
pubmed: 25995772
Am J Transl Res. 2019 Aug 15;11(8):4800-4808
pubmed: 31497200
Endocr Pract. 2012 Mar-Apr;18(2):140-5
pubmed: 21856595
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):800-804
pubmed: 30641811
Curr Pharm Des. 2017;23(10):1522-1532
pubmed: 28088910
Curr Ther Res Clin Exp. 2017 Jul 08;87:13-19
pubmed: 28912902
Curr Vasc Pharmacol. 2020;18(2):172-181
pubmed: 30961499
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Diabet Med. 2014 Apr;31(4):419-24
pubmed: 24151864
Diabetes Technol Ther. 2019 Dec;21(12):713-720
pubmed: 31385724
Cardiovasc Diabetol. 2017 May 22;16(1):69
pubmed: 28532406
Diabetes Care. 2003 May;26(5):1535-9
pubmed: 12716818
Curr Atheroscler Rep. 2008 Feb;10(1):55-60
pubmed: 18366986
Metabolism. 2019 Dec;101:154001
pubmed: 31672448
Diabet Med. 2012 Sep;29(9):1115-8
pubmed: 22288732
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):611-7
pubmed: 16385087
Med Sci Monit. 2020 Apr 02;26:e921891
pubmed: 32240122
Naunyn Schmiedebergs Arch Pharmacol. 2019 Jan;392(1):45-53
pubmed: 30206656
Ageing Res Rev. 2018 Sep;46:42-59
pubmed: 29803716
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Metabolism. 2014 Sep;63(9):1141-8
pubmed: 25034387
J Clin Endocrinol Metab. 2012 Jan;97(1):198-207
pubmed: 22013105
Diabetes Technol Ther. 2018 Oct;20(10):681-688
pubmed: 30096243
BMJ Open Diabetes Res Care. 2016 Aug 04;4(1):e000227
pubmed: 27547413
Diabetes Care. 2010 Aug;33(8):1734-7
pubmed: 20424219
Front Physiol. 2017 Dec 19;8:1077
pubmed: 29311992
JAMA. 2009 Sep 16;302(11):1186-94
pubmed: 19755697
PLoS One. 2015 Apr 21;10(4):e0123703
pubmed: 25897968
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Medicine (Baltimore). 2017 Sep;96(39):e8183
pubmed: 28953677
Diabetes Care. 2019 May;42(5):931-937
pubmed: 30885955
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
Mediators Inflamm. 2016;2016:3094642
pubmed: 27110066
Nat Med. 2018 Sep;24(9):1384-1394
pubmed: 30038219
Drugs R D. 2016 Sep;16(3):255-261
pubmed: 27333994
Diabetes Res Clin Pract. 2012 Oct;98(1):51-60
pubmed: 22682949
Diabetes Technol Ther. 2011 Feb;13(2):143-8
pubmed: 21284481
Cardiovasc Diabetol. 2019 Jun 5;18(1):76
pubmed: 31167663
Eur J Endocrinol. 2011 Jan;164(1):69-74
pubmed: 20961967
Nutr Metab Cardiovasc Dis. 2020 Jul 24;30(8):1236-1248
pubmed: 32571616
Endocr Pract. 2011 Mar-Apr;17(2):192-200
pubmed: 20841306
Endocrine. 2003 Apr;20(3):215-8
pubmed: 12721499
Hemodial Int. 2014 Apr;18(2):433-42
pubmed: 24405885
Int J Endocrinol. 2013;2013:976810
pubmed: 23762057
Curr Ther Res Clin Exp. 2017 Mar 10;84:26-31
pubmed: 28761576
Biosci Rep. 2018 Dec 21;38(6):
pubmed: 30473540
Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):691-6
pubmed: 17235413
Pharmacol Ther. 2020 May;209:107503
pubmed: 32061923
Drug Des Devel Ther. 2019 Aug 09;13:2769-2776
pubmed: 31496653
Eur J Pharmacol. 2019 Oct 15;861:172594
pubmed: 31412267
Respir Physiol Neurobiol. 2020 Feb;273:103316
pubmed: 31600583
Int Immunopharmacol. 2020 Jun;83:106372
pubmed: 32179246
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
Cardiovasc Diabetol. 2014 Feb 13;13:43
pubmed: 24521405
Circ Res. 2016 Aug 19;119(5):652-65
pubmed: 27418629
Clin Sci (Lond). 2018 Jun 12;132(11):1155-1168
pubmed: 29540537
Expert Opin Investig Drugs. 2010 Dec;19(12):1581-9
pubmed: 21105857
J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66
pubmed: 21558879
Expert Rev Clin Immunol. 2020 May;16(5):465-470
pubmed: 32237901